Legacy Healthcare is focused on the development of innovative treatments, particularly through its proprietary product, Coacillium. This product is being explored for various indications, including Alopecia Areata, persistent chemotherapy-induced alopecia, atopic dermatitis, and psoriasis. The company employs a structured pipeline approach that encompasses discovery, preclinical, clinical, filing, and approval stages, ensuring a comprehensive pathway from concept to market. Their commitment to advancing botanical drugs highlights a dedication to exploring natural solutions in healthcare.

In addition to their product development, Legacy Healthcare emphasizes collaboration with partners and a robust management team, which includes board investigators and advisors. This collaborative approach is essential for driving research and development efforts, as well as for staying informed about the latest advancements in the field. The company also actively engages in presenting late-breaking news and updates, such as those planned for the EADV 2024 conference, showcasing their commitment to transparency and communication within the healthcare community.

Switzerland

Legacy Healthcare is a Swiss-based biopharmaceutical company focused on leveraging the pleiotropic activity and strong safety profile of plants to develop prescription botanical drugs that address serious medical conditions.  

Our first product candidate, CINAINU, has demonstrated strong safety and efficacy in patients suffering from alopecia areata, a chronic autoimmune condition with highly damaging psycho-social issues that impact all who suffer from it, especially children.

Legacy Healthcare

Company Details